What the FDA labels say about taking them together
Amlodipine/telmisartan and ritonavir
Amlodipine/telmisartan's FDA label of January 30, 2023 names ritonavir in its drug interactions section; ritonavir's label does not name amlodipine/telmisartan itself but warns about its class (ARBs (angiotensin II receptor blockers), Calcium channel blockers, Calcium channel blockers (dihydropyridines)). The amlodipine/telmisartan label: “However, strong inhibitors of CYP3A4 may increase the plasma concentrations of amlodipine to a greater extent.”
Check it at the source: the amlodipine/telmisartan FDA label on DailyMed (effective January 30, 2023, Alembic Pharmaceuticals Limited); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the amlodipine/telmisartan label say about ritonavir?
Amlodipine/telmisartan label, drug interactionsHowever, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent.
Source: FDA drug label (Telmisartan and Amlodipine), Alembic Pharmaceuticals Limited, effective January 30, 2023 (SPL set 15b438b4-4874-43f4-a50a-4e6f3e5530ac), via openFDA; the full label on DailyMed
What does the ritonavir label say about amlodipine/telmisartan?
Ritonavir's label does not name amlodipine/telmisartan itself; it warns about its class (ARBs (angiotensin II receptor blockers), Calcium channel blockers, Calcium channel blockers (dihydropyridines)):
Ritonavir label, drug interactionsCalcium channel blockers: diltiazem, nifedipine, verapamil ↑ calcium channel blockers Caution is warranted and clinical monitoring of patients is recommended.
Ritonavir label, warnings and precautionsThe impact on the PR interval of co-administration of ritonavir with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amlodipine/telmisartan | Ritonavir | |
|---|---|---|
| Labeled for | High blood pressure | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $2.88 per unit 40-10 | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once